Pande Made S. Dharma Pathni
Medical Department, PT Kalbe Farma Tbk., Jakarta, Indonesia

Published : 6 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 6 Documents
Search

Terapi Diabetes dengan SGLT-2 Inhibitor Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 46, No 6 (2019): Diabetes Mellitus
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.471

Abstract

SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa.SGLT-2 is a glucose transporter located at renal proximal tubules and is responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Terapi Diabetes dengan GLP-1 Receptor Agonist Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 45, No 4 (2018): Cedera Kepala
Publisher : PT. Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i4.668

Abstract

GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyangGLP-1 become a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class is to lower glucagon hormone level, slow gastric emptying and induce satiety.  
Terapi Diabetes dengan SGLT-2 Inhibitor Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 46 No 6 (2019): Endokrinologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.442

Abstract

SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa. SGLT-2 is a glucose transporter located at renal proximal tubules and responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Tren Terapi Diabetes dengan GLP-1 Receptor Agonist Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 45 No 4 (2018): Neurologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i4.803

Abstract

GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyang.   GLP-1 becomes a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class are to lower glucagon hormone level, slow gastric emptying and induce satiety.
Terapi Diabetes dengan SGLT-2 Inhibitor Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 46 No 6 (2019): Endokrinologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v46i6.442

Abstract

SGLT-2 adalah transporter glukosa yang terletak di tubulus proksimal ginjal dan bertanggung jawab terhadap 90% reabsorpsi glukosa. Inhibisi terhadap transporter ini akan berdampak pada penurunan kadar glukosa darah dengan cara meningkatkan ekskresi glukosa melalui ginjal, namun kerjanya tergantung kadar glukosa. SGLT-2 is a glucose transporter located at renal proximal tubules and responsible for 90% glucose reabsorption. Inhibition to this transporter resulted in a decrease of blood glucose through increased renal glucose excretion, but the action is dependent on blood glucose level.
Tren Terapi Diabetes dengan GLP-1 Receptor Agonist Pande Made S. Dharma Pathni
Cermin Dunia Kedokteran Vol 45 No 4 (2018): Neurologi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v45i4.803

Abstract

GLP-1 menjadi target terapi DM tipe 2. Analog GLP-1 memiliki aktivitas serupa GLP-1 endogen, namun dengan kelebihan resisten terhadap deaktivasi enzim DPP-4, menghasilkan aktivitas yang lebih panjang. Manfaat lain obat golongan ini adalah menurunkan kadar hormon glukagon, memperlambat pengosongan lambung, dan menginduksi rasa kenyang.   GLP-1 becomes a therapeutic target of type 2 DM. Analogue of GLP-1 has the activity that mimics endogenous GLP-1, with advantages to be resistant to DPP-4 enzyme deactivation, resulting in longer activity. Other activities of this class are to lower glucagon hormone level, slow gastric emptying and induce satiety.